Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
First Claim
Patent Images
1. A compound of the following formula I or pharmaceutically acceptable salts thereof, or prodrug esters thereof, or stereoisomers thereof, or solvates thereof whereinA is a bond;
- a C1-C3 alkylene group optionally independently substituted on available atoms with one to six halo, hydroxy, alkoxy, hydroxyalkyl, SR4, alkyl, alkenyl, cyano, CONHR4, COOR4, oxo, NHOR4, ═
NOR4, or N(R8)COR4;
or a C2-C3 alkenylene group optionally independently substituted on available atoms with one to four halo, hydroxy, alkoxy, hydroxyalkyl, SR4, alkyl, alkenyl, cyano, CONHR4, COOR4, oxo, NHOR4, ═
NOR4, or N(R8)COR4;
with the proviso that A is a bond only when Z1a, Z2a and Z3a are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl; and
Z1b, Z2b and Z3b are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl;
B is carboxyl or tetrazole;
X and Y are independently —
O(CR5R6)q—
, —
(CR5R6)qO—
, —
(CR5R6)qN(R7)CO—
, —
N(R7)CO(CR5R6)q—
, —
N(R7)CO(CR5R6)qO—
, —
N(R7)CO(CR5R6)qC(O)O—
, —
N(R7)CO—
CR5═
CR6—
, —
(CR5R6)qN(R7)SO2—
, —
N(R7)SO2(CR5R6)q—
, —
O—
CO(CR5R6)q—
, —
O(CR5R6)qCO—
, —
(CR5R6)qO—
CO—
, or —
(CR5R6)qS(O)t—
;
R1 is aryl, heteroaryl, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, cylcoalkenyl or heterocyclo any of which may be optionally substituted with Z1a, Z2a and one or more Z3a;
R2 is aryl, heteroaryl, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, cylcoalkenyl or heterocyclo any of which may be optionally substituted with Z1b, Z2b and one or more Z3b;
R3 is H, OH, alkyl, hydroxyalkyl, aryl, nitro, halo, amino, alkylamino, alkoxy, cyano, thioalkyl, carboxyl, COOR4, NR7COR4, or NR7COOR4;
R4 is (1) H;
or (2) alkyl, haloalkyl, aminoalkyl, alkoxyalkyl, hydroxyalkyl, aryl or heteroaryl any of which may be optionally substituted with Z1c, Z2c and one or more Z3c;
R5 and R6 are independently (1) H, OH, halo, cyano or oxo;
or (2) alkoxy, alkyl, alkenyl, hydroxyalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylthio, aryloxy or heteroaryloxy any of which may be optionally substituted with Z1d, Z2d and one more Z3d;
R7 is (1) H, OH, or cyano;
or (2) alkoxy, alkyl, alkenyl, hydroxyalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylthio, aryloxy or heteroaryloxy any of which may be optionally substituted with Z1e, Z2e and one more Z3e;
R8 is (1) H, OH;
or (2) alkyl, aryl, heteroaryl, alkoxy, aryloxy, or alkenyl any of which may be optionally substituted with Z1f, Z2f and one or more Z3f;
t is 0, 1 or 2;
q is 0 to 5, Z1a-1f, Z2a-2f, and Z3a-3f are optional substituents independently selected from (1) V, where V is (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocylco)alkyl, heteroaryl, or (heteroaryl)alkyl;
(ii) a group (i) which is itself substituted by one or more of the same or different groups (i);
or (iii) a group (i) or (ii) which is independently substituted by one or more of the following groups (2) to (13) of the definition of Z1a, (2) —
OH or —
OV, (3) —
SH or —
SV, (4) —
C(O)pH, —
C(O)pV, or —
O—
C(O)V, where p is 1 or 2, (5) —
SO3H, —
S(O)pV, or —
S(O)pN(V1)V, (6) halo, (7) cyano, (8) nitro, (9) —
U1—
NV2V3, (10) —
U1—
N(V1)—
U2—
NV2V3, (11) —
U1—
N(V4)—
U2—
V, (12) —
U1—
N(V4)—
U2—
H, (13) oxo;
U1 and U2 are each independently (1) a single bond, (2) —
U3—
S(O)p—
U4—
, (3) —
U3—
C(O)—
U4—
, (4) —
U3—
C(S)—
U4—
, (5) —
U3—
O—
U4—
, (6) —
U3—
S—
U4—
, (7) —
U3—
O—
C(O)—
U4—
, (8) —
U3—
C(O)—
O—
U4—
, (9) —
U3—
C(═
NV1a)—
U4—
, or (10) —
U3—
C(O)—
C(O)—
U4—
;
V1,V1a,V2,V3 and V4 (1) are each independently hydrogen or a group provided in the definition of Z1a;
or (2) V2 and V3 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Z1a;
or (3) V2 or V3, together with V1, may be alkylene or alkenylene completing a 3- to 8-memberd saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Z1a;
or (4) V2 and V3 together with the nitrogen atom to which they are attached may combine to form a group —
N═
CV5V6 where V5 and V6 are each independently H or a group provided in the definition of V; and
U3 and U4 are each independently (1) a single bond, (2) alkylene, (3) alkenylene, or (4) alkynylene;
provided that said compound is other than a compound of formula X wherein R15 is H, hydroxy or alkoxy.
1 Assignment
0 Petitions
Accused Products
Abstract
Compounds that are dual aP2/k-FABP inhibitors are provided having the formula
wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
74 Citations
14 Claims
-
1. A compound of the following formula I
or pharmaceutically acceptable salts thereof, or prodrug esters thereof, or stereoisomers thereof, or solvates thereof wherein A is a bond; -
a C1-C3 alkylene group optionally independently substituted on available atoms with one to six halo, hydroxy, alkoxy, hydroxyalkyl, SR4, alkyl, alkenyl, cyano, CONHR4, COOR4, oxo, NHOR4, ═
NOR4, or N(R8)COR4;
ora C2-C3 alkenylene group optionally independently substituted on available atoms with one to four halo, hydroxy, alkoxy, hydroxyalkyl, SR4, alkyl, alkenyl, cyano, CONHR4, COOR4, oxo, NHOR4, ═
NOR4, or N(R8)COR4;
with the proviso that A is a bond only when Z1a, Z2a and Z3a are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl; and
Z1b, Z2b and Z3b are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl;
B is carboxyl or tetrazole;
X and Y are independently —
O(CR5R6)q—
,—
(CR5R6)qO—
,—
(CR5R6)qN(R7)CO—
,—
N(R7)CO(CR5R6)q—
,—
N(R7)CO(CR5R6)qO—
,—
N(R7)CO(CR5R6)qC(O)O—
,—
N(R7)CO—
CR5═
CR6—
,—
(CR5R6)qN(R7)SO2—
,—
N(R7)SO2(CR5R6)q—
,—
O—
CO(CR5R6)q—
,—
O(CR5R6)qCO—
,—
(CR5R6)qO—
CO—
, or—
(CR5R6)qS(O)t—
;
R1 is aryl, heteroaryl, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, cylcoalkenyl or heterocyclo any of which may be optionally substituted with Z1a, Z2a and one or more Z3a;
R2 is aryl, heteroaryl, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, cylcoalkenyl or heterocyclo any of which may be optionally substituted with Z1b, Z2b and one or more Z3b;
R3 is H, OH, alkyl, hydroxyalkyl, aryl, nitro, halo, amino, alkylamino, alkoxy, cyano, thioalkyl, carboxyl, COOR4, NR7COR4, or NR7COOR4;
R4 is (1) H;
or(2) alkyl, haloalkyl, aminoalkyl, alkoxyalkyl, hydroxyalkyl, aryl or heteroaryl any of which may be optionally substituted with Z1c, Z2c and one or more Z3c;
R5 and R6 are independently (1) H, OH, halo, cyano or oxo;
or(2) alkoxy, alkyl, alkenyl, hydroxyalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylthio, aryloxy or heteroaryloxy any of which may be optionally substituted with Z1d, Z2d and one more Z3d;
R7 is (1) H, OH, or cyano;
or(2) alkoxy, alkyl, alkenyl, hydroxyalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylthio, aryloxy or heteroaryloxy any of which may be optionally substituted with Z1e, Z2e and one more Z3e;
R8 is (1) H, OH;
or(2) alkyl, aryl, heteroaryl, alkoxy, aryloxy, or alkenyl any of which may be optionally substituted with Z1f, Z2f and one or more Z3f;
t is 0, 1 or 2;
q is 0 to 5, Z1a-1f, Z2a-2f, and Z3a-3f are optional substituents independently selected from (1) V, where V is (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocylco)alkyl, heteroaryl, or (heteroaryl)alkyl;
(ii) a group (i) which is itself substituted by one or more of the same or different groups (i);
or(iii) a group (i) or (ii) which is independently substituted by one or more of the following groups (2) to (13) of the definition of Z1a, (2) —
OH or —
OV,(3) —
SH or —
SV,(4) —
C(O)pH, —
C(O)pV, or —
O—
C(O)V, where p is 1 or 2,(5) —
SO3H, —
S(O)pV, or —
S(O)pN(V1)V,(6) halo, (7) cyano, (8) nitro, (9) —
U1—
NV2V3,(10) —
U1—
N(V1)—
U2—
NV2V3,(11) —
U1—
N(V4)—
U2—
V,(12) —
U1—
N(V4)—
U2—
H,(13) oxo;
U1 and U2 are each independently (1) a single bond, (2) —
U3—
S(O)p—
U4—
,(3) —
U3—
C(O)—
U4—
,(4) —
U3—
C(S)—
U4—
,(5) —
U3—
O—
U4—
,(6) —
U3—
S—
U4—
,(7) —
U3—
O—
C(O)—
U4—
,(8) —
U3—
C(O)—
O—
U4—
,(9) —
U3—
C(═
NV1a)—
U4—
, or(10) —
U3—
C(O)—
C(O)—
U4—
;
V1,V1a,V2,V3 and V4 (1) are each independently hydrogen or a group provided in the definition of Z1a;
or(2) V2 and V3 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Z1a;
or(3) V2 or V3, together with V1, may be alkylene or alkenylene completing a 3- to 8-memberd saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Z1a;
or(4) V2 and V3 together with the nitrogen atom to which they are attached may combine to form a group —
N═
CV5V6 where V5 and V6 are each independently H or a group provided in the definition of V; and
U3 and U4 are each independently (1) a single bond, (2) alkylene, (3) alkenylene, or (4) alkynylene;
provided that said compound is other than a compound of formula X wherein R15 is H, hydroxy or alkoxy. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
X and Y are independently —
O(CR5R6)q—
, —
(CR5R6)qO—
, —
N(R7)CO(CR5R6)qO—
, —
N(R7)CO(CR5R6)q—
—
N(R7)CO(CR5R6)qC(O)O—
, —
N(R7)CO—
CR5═
CR6—
, —
N(R7)SO2(CR5R6)q—
, or —
O(CR5R6)qCO—where q is 0, 1 or 2;
R1 is aryl, heteroaryl, cycloalkyl or alkyl, any of which may be optionally substituted with Z1a, Z2a and one more Z3a;
R2 is aryl, heeteroaryl, cycloalkyl or alkyl, any of which be optionally substituted with Z1b, Z2b and one more Z3b;
R3 is H, OH, halo, alkyl, haloalkyl or hydroxyalkyl;
R5 and R6 are independently (1)H or OH;
or(2) alkyl, aryl, aralkyl or heteroarylalkyl any of which may be optionally substituted with Z1d, Z2d and one or more Z3d; and
R7 is (1) H or OH;
or(2) alkyl, aryl, aralkyl or heteroarylalkyl any of which may be optionally substituted with Z1e, Z2e and one or more Z3e.
-
-
3. A compound of claim 1 wherein B is carboxyl or an ester thereof.
-
4. A compound of claim 2 wherein
A is a bond, or a C1-C2 alkylene group optionally substituted with one OH, SH, NH2, or NHOR4, or optionally substituted with at least one COOR4, halogen N(R8)COR4, hydroxyalkyl or oxo; -
X and Y are independently —
O(CR5R6)q—
, —
(CR5R6)qO—
, —
N R7)CO(CR5R6)q—
or —
N(R7)SO2(CR5R6)q—
;
where q is 0 or 1;
R1 is aryl, heteroaryl or C3-C6 cycloalkyl any of which may be optionally substituted with one or more Z1a, Z2a and one or more Z3a;
R2 is aryl, heteroaryl or C3-C6 cycloalkyl any of which may be optionally substituted with Z1b, Z2b and one or more Z3b;
R3 is H, OH, halo;
alkyl, or haloalkyl;
R5 and R6 are independently (1) H;
or(2) alkyl, aralkyl, or heteroarylalkyl any of which may be optionally substituted with Z1d, Z2d and one or more Z3d; and
R7 is (1) H;
or(2) alkyl, aralkyl, or heteroarylalkyl any of which may be optionally substituted with Z1d, Z2d and one or more Z3d.
-
-
5. A compound of claim 4 wherein
R1 is aryl or heteroaryl either of which may be optionally substituted with Z1a, Z2a and one or more Z3a; - and
R2 is aryl or heteroaryl either of which may be optionally substituted with Z1b, Z2b and one or more Z3ab.
- and
-
6. A compound of claim 5 wherein
Z1a, Z2a and Z3a are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl; - and
Z1b, Z2b and Z3b are independently halogen, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, aryloxy, aralkoxy, aryl, arylcarbonyl, carboxyl, cyano, nitro, oxo, arylsulfonylalkyl or alkylsulfonyl.
- and
-
7. A compound of claim 6 wherein B is carboxyl or an ester thereof.
-
8. A compound of claim 6 wherein R5, R6 and R7 are independently H, alkyl, aralkyl, or heteroarylalkyl.
-
9. A compound of claim 8 wherein
R5 and R6 are hydrogen; - and
R7 is hydrogen, alkyl, or aralkyl.
- and
-
10. A compound of claim 5 wherein
R1 is phenyl, napthyl, benzodioxolyl, benzodioxinyl, anthracenyl, pyridinyl, benzimidazolyl, quinoxalinyl, furanyl, thienyl, benzothiophenyl, or isothiozolyl any of which may be optionally substituted with Z1a, Z2a and one or more Z3a; - and
R2 is phenyl, napthyl, benzodioxolyl, benzodioxinyl, anthracenyl, pyridinyl, benzimidazolyl, quinoxalinyl, furanyl, thienyl, benzothiophenyl, or isothiozolyl any of which may be optionally substituted with Z1b, Z2b and one or more Z3b.
- and
-
11. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmacuetically acceptable vehicle or carrier therefor.
-
12. The pharmaceutical composition of claim 11 further comprising at least one additional therapeutic agent selected from antidiabetic agents, antihyperglycemic agents, hypolipidemic agents, antiobesity agents, antihypertensive agents, antiplatelet agents, antiinfective agents, anti-athersclerotic agents and anti-inflammatory agents.
-
13. The pharmaceutical composition of claim 12 wherein the other therapeutic agent is at least one antidiabetic agent selected from biguanides, sulfonyl ureas, glucosidase inhibitors, PPAR modulators, insulin sensitizers, glucagon-like peptide-1 (GLP-1), insulin or biguanide/glyburide combination.
-
14. The pharmaceutical composition of claim 13 wherein the antidiabetic agent is metformin, glyburide, glimepiride, glipyride, glipizide, chiorpropamide, gliclazide, acarbose, miglitol, troglitazone, rosiglitizone, piaglitazone, insulin, and/or metformin/glyburide combinations.
Specification